Our commitment: Sustainability & Impact

OUR INAUGURAL ESG ROADMAP

We are proud to share Gate2Brain’s inaugural ESG roadmap—an overview of our early efforts and growing commitment to responsible innovation.

As a biotech company working to break barriers in healthcare, we’ve developed a proprietary peptide-shuttle platform capable of crossing the blood–brain barrier. Our lead candidate, G2B-002, targets pediatric brain tumors, as a first indication, and opens the door to future treatments for neurological and systemic diseases.

Diversity, inclusion, and sustainability are part of our DNA. With a majority-women team and a rich mix of ages and backgrounds, we believe that diverse perspectives lead to better decisions and stronger science. Since 2022, we’ve been aligning our strategy with the UN Sustainable Development Goals, gradually embedding ESG principles into our operations, research, and governance.

This first roadmap presents our foundational pillars, initial milestones, and aspirations—underscoring Gate2Brain’s intention to grow with purpose and create long-term value for patients, people, and the planet.

1234

Mapping Gate2Brain’s Impact
Across the SDG’s

    • Our goal is to improve survival and quality of life through innovative, targeted drug delivery, starting with pediatric brain cancer.
    • Our lead candidate, G2B-002, has received Orphan Drug Designation in both Europe and the United States, accelerating its development and reinforcing our commitment to addressing critical unmet medical needs.
    • R&D to explore the application of our technology for other therapeutic modalities
     

  •  

    We promote gender equality through equal opportunities and a balanced team. Our Gender Equality Plan, in place since 2022, supports continuous improvement, and we actively advocate for women’s empowerment through outreach and professional networks.

    • Fair Labor Practices & Career Development: We ensure fair wages, safe working conditions, and opportunities for career growth, internal promotions, and continuous learning.
    • Work-Life Balance & Well-being: Our Remote Work Policy and Protocol for Digital Disconnection support work-life balance and respect personal time.
    • Inclusive Workplace Policies: We have comprehensive Prevention and Response Protocols to address harassment and discrimination, promoting an inclusive environment.
    • Professional Growth & Team Building: We organize retreats, team-building events, and training to foster team cohesion and career development.
    • Onboarding & Mentorship: Our Onboarding Protocol, Buddy Program, and Mentoring Program ensure smooth integration and continuous professional support.
    • Internal Communication: The Touch Points Internal Communication Program was launched in 2025 to enhance transparency, engagement, and communication across all levels of the organization.
     

  •  
    • Innovation in Drug Delivery: Gate2Brain is developing a cutting-edge peptide shuttle platform to enhance the delivery of therapeutic agents, overcoming biological barriers and improving drug efficacy across diverse therapeutic areas.
    • Collaboration for Advancement: Our in-house chemists work on synthesizing shuttle peptide-drug conjugates, building on prior developments to explore new applications.
    • Sustainable Practices:
      1. Our Supplier Code of Conduct outlines ethical and sustainable standards.
      2. We conduct regular audits to ensure compliance.
      3. Gate2Brain fosters sustainability awareness through close collaboration with partners.

  • Diverse Workforce
    Gate2Brain, founded five years ago, employs individuals ranging from 27 to 60 years old, from three different religions and countries, promoting inclusivity.

     

  •  

    Sustainable Production Practices: Gate2Brain continues its collaboration with its manufacturing partner to implement green chemistry principles in the synthesis of G2B-001, focusing on reducing solvent use and minimizing waste during production.

    • Commitment to Sustainability: G2B upholds the principles of the 3 R’s (Reduce, Reuse, Recycle) to protect terrestrial ecosystems and promote the humane treatment of animals, supporting biodiversity conservation.
    • Minimizing Animal Testing: We prioritize in vitro studies to reduce the reliance on animal testing, ensuring ethical research practices.
     

  •  
    • Strategic collaboration with SJD (Hospital Sant Joan de Déu) to develop G2B-002 for pediatric brain tumors, including high-grade gliomas, DIPG, and more.
    • Partnerships with two CDMOs and one CRO in India, supported by the CDTI Multipaís Program, to scale our technology efficiently and sustainably.
    • Collaboration with the Instituto de Parasitología y Biomedicina López-Neyra (IPBLN) to explore new drug delivery applications for our platform.

OUR INAUGURAL ESG ROADMAP

We are proud to share Gate2Brain’s inaugural ESG roadmap—an overview of our early efforts and growing commitment to responsible innovation.

As a biotech company working to break barriers in healthcare, we’ve developed a proprietary peptide-shuttle platform capable of crossing the blood–brain barrier. Our lead candidate, G2B-002, targets pediatric brain tumors, as a first indication, and opens the door to future treatments for neurological and systemic diseases.

Diversity, inclusion, and sustainability are part of our DNA. With a majority-women team and a rich mix of ages and backgrounds, we believe that diverse perspectives lead to better decisions and stronger science. Since 2022, we’ve been aligning our strategy with the UN Sustainable Development Goals, gradually embedding ESG principles into our operations, research, and governance.

This first roadmap presents our foundational pillars, initial milestones, and aspirations—underscoring Gate2Brain’s intention to grow with purpose and create long-term value for patients, people, and the planet.

Mapping Gate2Brain’s
Impact Across the SDG’s

  •  
    • Our goal is to improve survival and quality of life through innovative, targeted drug delivery, starting with pediatric brain cancer.
    • Our lead candidate, G2B-002, has received Orphan Drug Designation in both Europe and the United States, accelerating its development and reinforcing our commitment to addressing critical unmet medical needs.
    • R&D to explore the application of our technology for other therapeutic modalities

  •  

    We promote gender equality through equal opportunities and a balanced team. Our Gender Equality Plan, in place since 2022, supports continuous improvement, and we actively advocate for women’s empowerment through outreach and professional networks.

  •  
    • Fair Labor Practices & Career Development: We ensure fair wages, safe working conditions, and opportunities for career growth, internal promotions, and continuous learning.
    • Work-Life Balance & Well-being: Our Remote Work Policy and Protocol for Digital Disconnection support work-life balance and respect personal time.
    • Inclusive Workplace Policies: We have comprehensive Prevention and Response Protocols to address harassment and discrimination, promoting an inclusive environment.
    • Professional Growth & Team Building: We organize retreats, team-building events, and training to foster team cohesion and career development.
    • Onboarding & Mentorship: Our Onboarding Protocol, Buddy Program, and Mentoring Program ensure smooth integration and continuous professional support.
    • Internal Communication: The Touch Points Internal Communication Program was launched in 2025 to enhance transparency, engagement, and communication across all levels of the organization.

  •  
    • Innovation in Drug Delivery: Gate2Brain is developing a cutting-edge peptide shuttle platform to enhance the delivery of therapeutic agents, overcoming biological barriers and improving drug efficacy across diverse therapeutic areas.
    • Collaboration for Advancement: Our in-house chemists work on synthesizing shuttle peptide-drug conjugates, building on prior developments to explore new applications.
    • Sustainable Practices:
      1. Our Supplier Code of Conduct outlines ethical and sustainable standards.
      2. We conduct regular audits to ensure compliance.
      3. Gate2Brain fosters sustainability awareness through close collaboration with partners.

  •  

    Diverse Workforce
    Gate2Brain, founded five years ago, employs individuals ranging from 27 to 60 years old, from three different religions and countries, promoting inclusivity.

  •  

    Sustainable Production Practices: Gate2Brain continues its collaboration with its manufacturing partner to implement green chemistry principles in the synthesis of G2B-001, focusing on reducing solvent use and minimizing waste during production.

  •  
    • Commitment to Sustainability: G2B upholds the principles of the 3 R’s (Reduce, Reuse, Recycle) to protect terrestrial ecosystems and promote the humane treatment of animals, supporting biodiversity conservation.
    • Minimizing Animal Testing: We prioritize in vitro studies to reduce the reliance on animal testing, ensuring ethical research practices.

  •  
    • Strategic collaboration with SJD (Hospital Sant Joan de Déu) to develop G2B-002 for pediatric brain tumors, including high-grade gliomas, DIPG, and more.
    • Partnerships with two CDMOs and one CRO in India, supported by the CDTI Multipaís Program, to scale our technology efficiently and sustainably.
    • Collaboration with the Instituto de Parasitología y Biomedicina López-Neyra (IPBLN) to explore new drug delivery applications for our platform.
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social